CorMedix (CRMD) Receivables (2013 - 2026)
CorMedix (CRMD) posted Receivables of $171.2 million for Q4 2025, up 7.98% sequentially from $158.6 million in Q3 2025, and up 231.5% YoY from $51.7 million in Q4 2024.
CorMedix (CRMD) Receivables (2013 - 2026) Analysis & Trends
CorMedix has reported Receivables for 12 years, with the latest figure at $171.2 million in Q4 2025.
- Quarterly Receivables rose 231.5% year-over-year to $171.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $171.2 million (up 231.5% YoY) and the FY2025 annual result came in at $171.2 million, up 231.5% from the prior year.
- Receivables grew to $171.2 million in Q4 2025 per CRMD's latest filing, from $158.6 million in the prior quarter.
- Over five years, Receivables peaked at $171.2 million in Q4 2025 and troughed at $2975.0 in Q1 2022.
- A 4-year average of $45.2 million and a median of $17.4 million in 2024 frame the typical range for Receivables.
- The sharpest annual moves came in 2022 and 2025: Receivables tumbled 93.18% in 2022, then surged 5975.24% in 2025.
- Over 4 years, Receivables stood at $45368.0 in 2021, then tumbled by 93.44% to $2975.0 in 2022, then soared by 1736168.91% to $51.7 million in 2024, then jumped by 231.5% to $171.2 million in 2025.
- According to Business Quant data, Receivables over the past three periods registered $171.2 million, $158.6 million, and $42.9 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 2.13 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 6.57 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 1.93 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 160.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.06 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 912.74 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 1.09 Bn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 215.33 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 161.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 161.31 Mn |
| Dec 31, 2025 | 171.23 Mn |
| Sep 30, 2025 | 158.57 Mn |
| Jun 30, 2025 | 42.91 Mn |
| Mar 31, 2025 | 54.61 Mn |
| Dec 31, 2024 | 51.65 Mn |
| Sep 30, 2024 | 17.39 Mn |
| Jun 30, 2024 | 706,337.00 |
| Mar 31, 2022 | 2,975.00 |
| Dec 31, 2021 | 45,368.00 |
| Jun 30, 2021 | 3,180.00 |
| Mar 31, 2021 | 43,606.00 |
| Dec 31, 2020 | 3,357.00 |
| Sep 30, 2020 | 6,118.00 |
| Jun 30, 2020 | 11,030.00 |
| Mar 31, 2020 | 7,311.00 |
| Dec 31, 2019 | 35.00 |
| Sep 30, 2019 | 3,956.00 |
| Mar 31, 2019 | 34,381.00 |
| Dec 31, 2018 | 10,904.00 |